ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer
Results of a retrospective study presented during the 2021 American [...]
Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer
The microbes in the gut (the gut microbiome) are a [...]
Age-based outcomes in kidney cancer patients treated with first-line targeted therapy or immunotherapy
This study compared disease outcomes, treatments, and dose reductions in [...]
Checkpoint inhibitor re-challenge after immune-related adverse events
Immunotherapy has revolutionised treatment in many cancers, including renal cell [...]
Nephritis as a potential predictor of response to immune checkpoint inhibitors in kidney cancer
This study, to be published in Journal for Immunotherapy of [...]
γ-Glutamyltransferase as a biomarker in patients on nivolumab for metastatic kidney cacner
A protein called γ-glutamyltransferase can predict survival in patients with [...]
Safety and efficacy of tivozanib–nivolumab combination in patients with metastatic kidney cancer
In this phase 1b/2 study the researchers looked at a [...]
Immune-related adverse events from cabozantinib plus atezolizumab as first-line treatment for advanced kidney cancer
The COSMIC-021 clinical trial investigated a combination of cabozantinib and [...]
Cabozantinib plus atezolizumab for non-clear cell renal cell carcinoma
In this video interview with Dr Monty Pal from the [...]
Treatment selection for metastatic kidney cancer based on gene expression
The discovery of a reliable biomarker for metastatic renal cell [...]
